Morgan Stanley Arvinas, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Arvinas, Inc. stock. As of the latest transaction made, Morgan Stanley holds 522,593 shares of ARVN stock, worth $12.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

522,593

Previous 779,791 32.98%

Holding current value

$12.6 Million

Previous $20.8 Million 37.99%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.66 - $32.73 $6.09 Million - $8.42 Million	-257,198 Reduced 32.98%	522,593 $12.9 Million
Q2 2024 Oct 17, 2024	BUY	$24.46 - $40.4 $2.55 Million - $4.21 Million	104,282 Added 15.44%	779,791 $20.8 Million
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $2.55 Million - $4.21 Million	104,282 Added 15.44%	779,791 $20.8 Million
Q1 2024 Oct 17, 2024	SELL	$36.38 - $52.31 $3.79 Million - $5.45 Million	-104,282 Reduced 13.37%	675,509 $27.9 Million
Q1 2024 Aug 16, 2024	SELL	$36.38 - $52.31 $653,748 - $940,010	-17,970 Reduced 2.59%	675,509 $27.9 Million
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $653,748 - $940,010	-17,970 Reduced 2.59%	675,509 $27.9 Million
Q4 2023 Aug 16, 2024	SELL	$14.19 - $42.33 $1.22 Million - $3.65 Million	-86,312 Reduced 11.07%	693,479 $28.5 Million
Q4 2023 Feb 13, 2024	BUY	$14.19 - $42.33 $4.1 Million - $12.2 Million	289,157 Added 71.52%	693,479 $28.5 Million
Q3 2023 Nov 15, 2023	SELL	$19.64 - $28.21 $930,523 - $1.34 Million	-47,379 Reduced 10.49%	404,322 $7.94 Million
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $1.18 Million - $1.71 Million	54,409 Added 13.69%	451,701 $11.2 Million
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $2.24 Million - $3.19 Million	85,706 Added 27.51%	397,292 $10.9 Million
Q4 2022 Feb 14, 2023	SELL	$32.47 - $57.24 $2.6 Million - $4.58 Million	-80,022 Reduced 20.43%	311,586 $10.7 Million
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $147,508 - $204,298	3,523 Added 0.91%	391,608 $17.4 Million
Q2 2022 Oct 27, 2022	BUY	$36.01 - $74.24 $5.86 Million - $12.1 Million	162,652 Added 72.15%	388,085 $16.3 Million
Q2 2022 Aug 15, 2022	BUY	$36.01 - $74.24 $5.86 Million - $12.1 Million	162,652 Added 72.15%	388,085 $16.3 Million
Q1 2022 Oct 27, 2022	SELL	$60.27 - $81.57 $9.8 Million - $13.3 Million	-162,652 Reduced 41.91%	225,433 $15.2 Million
Q1 2022 May 13, 2022	SELL	$60.27 - $81.57 $1.39 Million - $1.88 Million	-23,103 Reduced 9.3%	225,433 $15.2 Million
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $32.7 Million - $47.7 Million	-496,183 Reduced 66.63%	248,536 $20.4 Million
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $54.5 Million - $80.3 Million	744,719 New	744,719 $61.2 Million

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.29B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account